Physician profile
Ijaz Rashid
NPI 1003138058
$5,325.51
in general payments reported to CMS, 2019-2025
34 companies · $2,070 in 2025
The $2,070 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $72.46 · 2021: $140 · 2022: $842 · 2023: $358 · 2024: $862 · 2025: $2,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.19 | 2022-2025 | |
| Genentech USA, INC. | $985.53 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Pfizer INC. | $345.17 | 2023-2025 | |
| Tg Therapeutics, INC. | $308.68 | 2024-2025 | |
| Amgen INC. | $269.88 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $245.61 | 2019-2020 | |
| Lundbeck LLC | $239.29 | 2024-2025 | Vyepti |
| Eisai INC. | $212.65 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $177.62 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $167.48 | 2019-2024 | Austedo Xr |
| Medtronic, INC. | $115.79 | 2025 | Percept PC Brainsense |
| Livanova USA, INC. | $114.20 | 2019 | |
| Sk Life Science, INC. | $104.26 | 2025 | |
| Neurocrine Biosciences, INC. | $102.69 | 2019-2025 | Ingrezza |
| Ucb, INC. | $90.80 | 2019-2025 | Rystiggo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $77.59 | 2019-2025 | Nuplazid |
| Averitas Pharma INC. | $74.78 | 2025 | Qutenza |
| Emd Serono, INC. | $70.04 | 2019 | |
| Argenx US, INC. | $56.08 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Genzyme Corporation | $49.76 | 2019-2020 | |
| Acorda Therapeutics, INC | $44.82 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.52 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $40.88 | 2024-2025 | Dysport |
| Biogen, INC. | $40.73 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $40.52 | 2019 | |
| Lilly USA, LLC | $40.31 | 2025 | Kisunla |
| Amneal Pharmaceuticals LLC | $36.55 | 2019-2025 | Crexont |
| Takeda Pharmaceuticals U.S.A., INC. | $29.72 | 2025 | Hyqvia |
| Abbott Laboratories | $23.48 | 2025 | Infinity |
| Merz Pharmaceuticals, LLC | $19.47 | 2025 | Xeomin |
| Boston Scientific Corporation | $15.00 | 2019 | |
| Ge Healthcare | $13.43 | 2024 | |
| Avanir Pharmaceuticals, INC. | $13.42 | 2019 | |
| Mdd US Operations, LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ijaz Rashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.